A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Condition: Factor XIII Deficiency
MeSH terms: Factor XIII Deficiency
Intervention: FXIII Concentrate (Human)
Intervention description: Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.
Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion.
Intervention MeSH terms: Fibrinolysin
Phase: Phase 3
Study type: Interventional
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 41.0
Sex: All
Healthy volunteers: No
Keywords: Hereditary Factor XIII deficiency; Factor XIII

Summary:

      Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder
      associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to
      patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood
      in the usual clotting process, thereby preventing bleeding.

      In this study, patients will be treated with FXIII Concentrate (Human) and followed closely
      to determine that they receive the dose that will best minimize the chance of bruising and
      bleeding.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent/assent for study participation obtained before undergoing any
             study-specific procedures

          -  Documented congenital FXIII deficiency which requires prophylactic treatment with a
             FXIII containing product.

          -  Males and females of any age with congenital FXIII deficiency

          -  Received full hepatitis B vaccination and/or is hepatitis B surface antibody positive

        Exclusion Criteria:

          -  Diagnosis of acquired FXIII deficiency

          -  Administration of a FXIII-containing product, including blood transfusions or other
             blood products within 4 weeks prior to the planned Day 0

          -  Any known congenital or acquired coagulation disorder other than congenital FXIII
             deficiency

          -  Known or suspected to have antibodies towards FXIII

          -  Use of any other investigational medicinal product within 4 weeks prior to the
             Baseline Visit (Day 0)

          -  Known Positivity for human immunodeficiency virus (HIV) or a positive result for HIV
             at the Screening Visit of this study or the FXIII study 2002 (NCT00883090).

          -  Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) concentration
             >2.5 times the upper limit of normal at the Screening Visit of this study or at the
             Day 56 Visit of Factor XIII Study BI71023_2002 (NCT00883090)

          -  Fibrinogen level less than 85% of the lower limit of normal at the Screening Visit of
             this study or the Factor XIII Study BI71023_2002 (NCT00883090)

          -  Active bleeding ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
             and/or ≥ moderate between the Screening and Baseline Visits

          -  Pregnant or breast-feeding

          -  Intention to become pregnant during the course of the study

          -  Female subjects of childbearing potential not using, or not willing to use, a
             medically reliable method of contraception for the entire duration of the study

          -  Suspected inability (e.g., language problems) or unwillingness to comply with study
             procedures or history of noncompliance